Administration of recombinant human erythropoietin in patients with gynecological cancer before radical surgery.

The purpose of this prospective study was to investigate the efficacy of preoperative administration of recombinant human erythropoietin in patients with gynecological cancer.
The study included 38 women with gynecological cancer who were divided randomly in two groups. Study group A included 20 women with gynecological cancer who received recombinant human erythropoietin (rHuEPO) plus iron supplementation for ten days before surgery and five days postoperatively. Group B (controls) included 18 patients who received only iron supplementation for the same time period. Blood samples were obtained on days -10, -3, 0, +3, +5, +10.
The mean hemoglobin level was significantly higher in group A than in group B on the day of the operation and remained significantly higher postoperatively while an inverse relationship was observed for mean ferritin values in the two groups.
Preoperative administration of rHuEPO in patients with gynecological cancer seems to be effective in the blood management of these patients.
AuthorsV Dousias, T Stefos, I Navrozoglou, I Staikos, A Ditto, E Paraskevaidis
JournalClinical and experimental obstetrics & gynecology (Clin Exp Obstet Gynecol) Vol. 32 Issue 2 Pg. 129-31 ( 2005) ISSN: 0390-6663 [Print] Italy
PMID16108399 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Iron Compounds
  • Recombinant Proteins
  • Erythropoietin
  • Adult
  • Aged
  • Confidence Intervals
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Erythropoietin (administration & dosage)
  • Female
  • Follow-Up Studies
  • Genital Neoplasms, Female (drug therapy, mortality, pathology, surgery)
  • Gynecologic Surgical Procedures (methods, mortality)
  • Humans
  • Iron Compounds (administration & dosage)
  • Middle Aged
  • Neoplasm Staging
  • Preoperative Care
  • Probability
  • Prospective Studies
  • Recombinant Proteins
  • Reference Values
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: